Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 12 · below the Ichimoku cloud · RSI 13 (oversold) · MACD above its signal · at its 52-week low
| 0.1056 | 52-week high | +105500.00% |
| 0.000400 | Previous month high | +300.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in YECO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a YECO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for YECO.
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.2 | 0.1 | -36.1 | -4.8 | -70.0 | -98.7 | 100.0 | 0.0 | -75.0 | 0.0 | −99.9% | ||
| 2025 | 6.0 | -15.0 | 0.1 | 1.4 | -1.3 | 3.4 | -9.2 | 0.2 | 4.5 | 18.1 | 0.0 | -18.9 | −15.1% |
| 2024 | -29.8 | 0.1 | 0.1 | -11.6 | -10.8 | -49.6 | -7.1 | 0.0 | 32.1 | -30.1 | -12.4 | -54.5 | −90.5% |
| 2023 | -44.1 | 0.0 | -12.6 | 20.5 | -5.0 | -26.0 | 47.9 | 60.6 | -58.1 | 114.2 | -25.3 | -10.7 | −41.2% |
| 2022 | 11.1 | -32.8 | -9.1 | 9.5 | 4.7 | -28.5 | -14.6 | 32.5 | -10.3 | -12.9 | 276.4 | 13.3 | +109.9% |
| 2021 | -15.0 | 0.7 | -12.4 | 37.3 | -3.3 | -23.7 | -7.9 | 12.6 | -11.4 | -14.9 | -69.7 | -10.0 | −83.8% |
| 2020 | 0.0 | -18.1 | 313.6 | -70.6 | 430.0 | -43.4 | -6.7 | 499.6 | 96.4 | 3.0 | -23.5 | 284.6 | +9860.2% |
| 2019 | -32.9 | -43.4 | -63.3 | 19.3 | 14.1 | -53.3 | 7.4 | 47.6 | 80.1 | -69.9 | 1.7 | -17.8 | −93.6% |
| 2018 | 14.8 | 3.2 | -2.5 | 2.6 | -5.0 | -13.2 | -29.9 | -22.7 | 2.1 | 300.7 | -1.7 | -86.3 | −70.7% |
| 2017 | 9.7 | 1.1 | -9.3 | -31.8 | -8.3 | -7.6 | -88.2 | 106.5 | -59.6 | 1080.2 | 14.9 | -20.4 | −38.3% |
| 2016 | -33.4 | 28.0 | 5.3 | 0.5 | -18.9 | -47.4 | 22.0 | 15.8 | -3.7 | -27.7 | -33.2 | -22.2 | −80.4% |
| 2015 | -30.8 | 32.5 | -60.9 | 17.2 | 3.6 | 70.9 | −25.7% |
No analyst coverage for this instrument.
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
No recent headlines.